Acrivon Therapeutics (NASDAQ:ACRV) Upgraded to “Hold” at Wall Street Zen

Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts also recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Piper Sandler boosted their target price on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Finally, HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Acrivon Therapeutics Stock Down 3.2%

Shares of NASDAQ:ACRV opened at $1.53 on Friday. Acrivon Therapeutics has a 12-month low of $1.05 and a 12-month high of $5.96. The business has a 50 day moving average of $2.01 and a 200-day moving average of $1.89. The stock has a market cap of $48.29 million, a PE ratio of -0.72 and a beta of 1.74.

Insider Activity at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen purchased 49,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average price of $1.68 per share, with a total value of $82,320.00. Following the completion of the purchase, the chief executive officer directly owned 2,095,771 shares in the company, valued at $3,520,895.28. This trade represents a 2.39% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders acquired a total of 67,832 shares of company stock valued at $114,534 in the last quarter. 11.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of large investors have recently bought and sold shares of ACRV. Invesco Ltd. acquired a new position in shares of Acrivon Therapeutics in the 1st quarter valued at approximately $72,000. XTX Topco Ltd bought a new position in Acrivon Therapeutics in the second quarter valued at approximately $126,000. Quadrature Capital Ltd acquired a new position in Acrivon Therapeutics during the second quarter valued at approximately $26,000. Jane Street Group LLC acquired a new position in Acrivon Therapeutics during the second quarter valued at approximately $371,000. Finally, UBS Group AG lifted its stake in Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after purchasing an additional 682,763 shares during the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.